{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:22:35Z","timestamp":1760782955730},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11906-005-0067-3","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:10:51Z","timestamp":1180059051000},"page":"343-347","source":"Crossref","is-referenced-by-count":23,"title":["The role of aldosterone antagonists in the management of resistant hypertension"],"prefix":"10.1007","volume":"7","author":[{"given":"Mari K.","family":"Nishizaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"67_CR1","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"67_CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393\u2013404.","journal-title":"J Clin Hypertens"},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","volume":"19","author":"AG Logan","year":"2001","unstructured":"Logan AG, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001, 19:2271\u20132277. This study reports that unsuspected obstructive sleep apnea is common in subjects with resistant hypertension, particularly males.","journal-title":"J Hypertens"},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/sleep\/24.6.721","volume":"24","author":"P Lavie","year":"2001","unstructured":"Lavie P, Hoffstein V: Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep 2001, 24:721\u2013725.","journal-title":"Sleep"},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896. This study provides strong evidence that primary hyperaldosteronism is a common cause of treatment resistance in black and white subjects.","journal-title":"Hypertension"},{"key":"67_CR6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"BJ Gallay","year":"2001","unstructured":"Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"IK Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217\u20132226. Amiloride is shown to be broadly effective in subjects with low renin-resistant hypertension supporting aldosterone excess as a common cause of resistance of blood pressure treatment.","journal-title":"J Hypertens"},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MA Nishizaka","year":"2003","unstructured":"Nishizaka MA, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930. Spironolactone is demonstrated to provide significant blood pressure reduction in patients with resistant hypertension.","journal-title":"Am J Hypertens"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","volume":"166","author":"P Romagni","year":"2003","unstructured":"Romagni P, Rossi F, Guerrini L, et al.: Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003, 166:345\u2013349.","journal-title":"Atherosclerosis"},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155.","journal-title":"J Am Coll Cardiol"},{"key":"67_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123.","journal-title":"Hypertension"},{"key":"67_CR13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0091270003258189","volume":"43","author":"LM Prisant","year":"2003","unstructured":"Prisant LM, Krum H, Roniker B: Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003, 43:1203\u20131210.","journal-title":"J Clin Pharmacol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0067-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-005-0067-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0067-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:13Z","timestamp":1559434573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-005-0067-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s11906-005-0067-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}